Source link : https://newshealth.biz/health-news/subcutaneous-pembro-vs-iv-in-nsclc/
For patients with metastatic non–small cell lung cancer (NSCLC), subcutaneous (SC) administration of pembrolizumab works just as well as standard intravenous (IV) administration, phase 3 data indicated. Importantly, SC pembrolizumab saves time “potentially streamlining treatment center workflows and lowering healthcare resource utilization,” said Enriqueta Felip, MD, PhD, in a presentation at the European Lung Cancer […]
The post Subcutaneous Pembro vs IV in NSCLC first appeared on News Health.
Author : News Health
Publish date : 2025-03-31 07:21:00
Copyright for syndicated content belongs to the linked Source.